Grass allergy immunotherapy gets green light in Germany

UK-based immunology specialist Allergy Therapeutics (AIM: AGY) has announced that the Paul Ehrlich Institut (PEI) has granted a marketing authorization in Germany for the group's subcutaneous grass pollen allergen immunotherapy, Grass MATA MPL.

The product, which will be commercialized in the German market as Grassmuno, is a subcutaneous allergen immunotherapy containing a unique mixture of allergen extracts from grass pollen and Allergy’s novel adjuvant system, monophosphoryl lipid-A and the biodegradable depot adjuvant microcrystalline tyrosine, to increase the immunotherapy's immunogenic effect.

The approval marks the first subcutaneous grass-pollen immunotherapy to be authorized by PEI through its Therapieallergene-Verordnung (TAV) framework and follows the submission of a comprehensive evidence package of quality, safety and clinical efficacy including Allergy’s pivotal Phase III G306 trial in adults.